SK3 Group Inc. (SKTO)

[Raggedy Man]

On the news today, the TITLE has not changed but the content is different. By Paragraph.

Jan 10th- LOS ANGELES, CA--(Marketwired - Jan 10, 2014) - SK3 Group, Inc (OTC Pink: SKTO) is pleased to announce that it has completed the licensing agreements between Berkeley Bio-Organic Research Laboratories, LLC and its managed wholesale collectives to produce non-psychoactive mixed cannabinoid carboxylates (Dharmanol™). The licensing agreement covers the proprietary methods developed by Berkeley Bio -- known as cryo-extraction -- used to extract the cannabinoids and preserve them in their non-psychoactive state.

Jan 13th- LOS ANGELES, CA--(Marketwired - Jan 13, 2014) - SK3 Group, Inc. (OTC Pink: SKTO) ("the Company") is pleased to announce that Berkeley Bio-Organic Research Laboratories is seeking participants to test their new proprietary cannabinoid-based skin care products -- Dharmanol™ Topikoil™, and T-Hydrocan™ Topikoil™.

______________________________

Jan 10th- "We are happy to have put together more of the elements necessary to fill the large demand anticipated for our Dharmanol™ product line," said Artemus Mayor, President of SK3 Group. "Dr. Charles Apel and David Hoye have developed a unique technique for extracting the non-psychoactive but effective components of cannabis that we believe will prove to be the key to bringing an entirely new dimension to the field of nutritional supplements in the United States and greater access to the beneficial effects of medical marijuana."

Jan 13th- Numerous scientific studies, as well as a host of anecdotal evidence, have shown that phyto-cannabinoids, and other elements of cannabis / hemp, are active against various types of skin disease. Research by Manuel Guzman at Complutense University in Madrid, Spain has shown that cannabinoids decreased cancer cell proliferation and spreading, decreased density of blood vessels that provide nutrients to tumors, increased cancer cell death, and inhibited tumor-cell metastatic spreading into nearby organs. Much anecdotal evidence on the internet and elsewhere has shown that cannabis oil, when placed on a wart, mole, discoloration, or other growth, can cause numerous types of skin imperfections to simply disappear in just a few weeks with daily treatment.

Berkeley Bio will be testing two types of its proprietary Topikoil™. T-Hydrocan™ Topikoil™ will be made with a substantial dose of whole-plant cannabis extract containing fully activated (decarboxylated) cannabinoids, as well as a wide array of terpenes, terpenoids, and other steam-soluble elements of cannabis / hemp. Dharmanol™ Topikoil™ contains non-psychoactive CBD (cannabidiol) and a wide array of other non-psychoactive cannabinoids from cannabis / hemp.

While the initial testing and rollout will focus on medical cannabis patients in California, the Company intends to roll out Dharmanol™ Topikoil™ nationwide based on the applicable regulations of each state and the US Government.

Those wishing to participate will be provided with several different topical preparations (lotions / salves) and will be required to live in California and keep accurate records, including taking before and after pictures. The testing will begin in one to two months. To sign up, please email your contact information to [e-mail].

"We are very pleased to be announcing these new products," said Artemus Mayor, President of the Company. "Research has shown very significant effectiveness of medical cannabis against a wide variety of skin ailments, and the stories on the Internet of people casually treating skin imperfections with cannabis topicals abound. Not only is this product chemically different than other similar products on the market, but our new products will have consistent, measurable medical cannabis content that should lead to more effective and targeted dosing. Adding this new delivery system to our Dharmanol™ line of products will substantially increase our market reach into new areas, directly benefiting our bottom line. In addition, our experience with these new products will assist in our development of an extended release transdermal patch product as well as other products."

http://finance.yahoo.com/news/medical-greens-skto-announces-licensing-145257517.html

http://finance.yahoo.com/news/sk3-group-skto-announces-licensing-163947351.html